Merrimack Pharmaceuticals, Inc. Patent applications |
Patent application number | Title | Published |
20160122438 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 05-05-2016 |
20160122411 | CARTILAGE-BINDING FUSION PROTEINS - Provided herein are fusion proteins comprising a first domain that specifically binds to the extracellular domain of a growth factor receptor, and a second domain that specifically binds to a cartilage matrix component, and pharmaceutical composition comprising these fusion proteins. Methods of treating musculoskeletal diseases using the fusion proteins and pharmaceutical composition disclosed herein are also provided. | 05-05-2016 |
20160017046 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC BONE DISORDERS - Provided are compositions comprising one of more molecules that specifically bind to CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) and methods for treating and improving the symptoms of pathologic bone loss in a subject by administering to the subject a therapeutically effective amount of such compositions. | 01-21-2016 |
20150231238 | OVERCOMING RESISTANCE TO ERBB PATHWAY INHIBITORS - Provided are methods for overcoming resistance to an ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor. The resistance may be acquired resistance to an EGFR inhibitor, such as acquired resistance to gefitinib. In the methods provided, a subject exhibiting resistance to an ErbB pathway inhibitor is selected and both an ErbB 3 inhibitor and a second ErbB pathway inhibitor are administered to the subject, such as an EGFR inhibitor or a HER2 inhibitor. Also provided are methods for inhibiting the growth of a tumor comprising a T790M EGFR mutation by contacting the tumor with an ErbB3 inhibitor and an EGFR inhibitor. Compositions for overcoming resistance to an ErbB pathway inhibitor, comprising both an ErbB 3 inhibitor and a second ErbB pathway inhibitor, such as an EGFR inhibitor or a HER2 inhibitor, are also provided. | 08-20-2015 |
20150202287 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or T-DM 1, and/or combinations thereof; and an effective amount of a 10 bispecific anti-ErbB2/anti-ErbB3 antibody. | 07-23-2015 |
20150182521 | METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN - Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin. | 07-02-2015 |
20150139936 | DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTI-CANCER THERAPEUTICS - Provided are methods and compositions for clinical treatment of advanced HER2 positive solid tumors cancer using combination therapies comprising bispecific anti-ErbB2/anti-ErbB3 antibodies. | 05-21-2015 |
20150093328 | COMPOSITIONS AND METHODS FOR NON-INVASIVE IMAGING - The present invention relates to a novel composition useful in targeted diagnostic and/or therapy of a target site, such as cancerous tissue. The composition and methods disclosed herein find particular use in diagnosing and imaging cancerous tissue. The present invention provides a new diagnostic tool for the utilization of positron emission tomography (PET) imaging technique. | 04-02-2015 |
20140302035 | ANTI-C-MET Tandem Fc Bispecific Antibodies - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-09-2014 |
20140294834 | TANDEM FC BISPECIFIC ANTIBODIES - Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific. | 10-02-2014 |
20140248280 | ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH PACLITAXEL FOR TREATMENT OF GYNECOLOGICAL CANCERS - Provided are methods and compositions for clinical treatment of advanced gynecological cancers using anti-ErbB3 antibodies combined with paclitaxel. | 09-04-2014 |
20140234329 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 08-21-2014 |
20140234317 | METHODS FOR PREVENTING TOXIC DRUG-DRUG INTERACTIONS IN COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-ErbB3 agent, such as an anti-ErbB3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-ErbB3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity. In a reduced dosage, the amount of drug administered per unit time is reduced as compared to a dose that would be administered if the drug was administered as monotherapy. The reduced dosage can be, for example, a reduced drug dose or a reduced drug dosing frequency, or both. Compositions useful in practicing the disclosed methods are also provided. | 08-21-2014 |
20140234314 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF - Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed. | 08-21-2014 |
20140178380 | Bi-Specific Fusion Proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network. | 06-26-2014 |
20140170668 | MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS - Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations. | 06-19-2014 |
20140154298 | LIPOSOMES USEFUL FOR DRUG DELIVERY - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provides methods of making the liposome compositions provided by the present invention. | 06-05-2014 |
20140134170 | USE OF INHIBITORS OF EGFR-FAMILY RECEPTORS IN THE TREATMENT OF HORMONE REFRACTORY BREAST CANCERS - Provided are methods of suppressing growth of hormone refractory breast tumors by contacting tumor cells with an ErbB3 inhibitor, preferably an anti-ErbB3 antibody. Also provided are methods for treating hormone refractory breast cancer in a patient by administering to the patient an inhibitor of heregulin binding to ErbB3 or to ErbB2/ErbB3 heterodimer, which inhibitor is an anti-ErbB3 antibody or an anti-ErbB2 antibody. The treatment methods can further comprise selecting a patient having a hormone refractory breast cancer and then administering the inhibitor to the patient. The treatment methods may also comprise administering an estrogen receptor antagonist, or an aromatase inhibitor to the patent and may at further comprise administering to the patient at least one additional anti-cancer agent that is not an ErbB3 inhibitor, an estrogen receptor antagonist, or an aromatase inhibitor to the patient in combination with the ErbB3 inhibitor. | 05-15-2014 |
20140127238 | METHODS, SYSTEMS AND PRODUCTS FOR PREDICTING RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT AND TREATING A PATIENT ACCORDING TO THE PREDICTED RESPONSE - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. | 05-08-2014 |
20140127207 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF - Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed. | 05-08-2014 |
20140127136 | LIPOSOMES USEFUL FOR DRUG DELIVERY TO THE BRAIN - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. The present invention also provides for the methods and kits for the delivery of liposomal compositions to the brain. | 05-08-2014 |
20140079703 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS - Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof; and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof. | 03-20-2014 |
20140017264 | DOSAGE AND ADMINISTRATION OF BISPECIFIC SCFV CONJUGATES - Disclosed are methods for the therapeutic administration of bispecific scFv conjugates as single doses at at least weekly intervals. In certain embodiments the conjugate is MM-111 and is administered at intervals of every two weeks or every three weeks. In other embodiments a single loading dose of MM-111 is administered to a human patient followed at at least weekly intervals by a least a single maintenance dose of MM-111. The loading dose is larger than the maintenance dose. | 01-16-2014 |
20130236459 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 09-12-2013 |
20130183311 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided. | 07-18-2013 |
20130131317 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 05-23-2013 |
20130034548 | USE OF ERBB3 INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE AND BASAL-LIKE BREAST CANCERS - Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor. | 02-07-2013 |
20120308576 | MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS - Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations. | 12-06-2012 |
20120269812 | MONOSPECIFIC AND BISPECIFIC ANTI-IGF-1R AND ANTI-ERBB3 ANTIBODIES - Provided herein are novel monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. Novel antiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided. | 10-25-2012 |
20120259093 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 10-11-2012 |
20120244163 | BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF - Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways. | 09-27-2012 |
20120177652 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agents are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding domain that binds specifically to a second cell surface marker, causing a significant and desired biological effect. Compositions of such bispecific binding agents, uses for them, and kits containing them are also provided. | 07-12-2012 |
20120087934 | COADMINISTRATION OF ALPHA-FETOPROTEIN AND AN IMMUNOMODULATORY AGENT TO TREAT MULTIPLE SCLEROSIS - The present invention features methods for treating multiple sclerosis by administering an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents to a patient in need thereof. Also disclosed are compositions and kits that contain an alpha-fetoprotein polypeptide (or a biologically active fragment, derivative, or analog thereof) and one or more immunomodulatory agents. | 04-12-2012 |
20120003221 | HUMAN SERUM ALBUMIN LINKERS AND CONJUGATES THEREOF - Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. | 01-05-2012 |
20110293579 | Bi-specific fusion proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration. | 12-01-2011 |
20110159513 | METHODS AND SYSTEMS FOR PREDICTING RESPONSE OF CELLS TO A THERAPEUTIC AGENT - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. | 06-30-2011 |
20110125468 | USING RESPONSE SURFACES FOR SCREENING INHIBITOR COMBINATIONS AND DIGITAL PROCESSING METHODS - A method for selecting a combination of therapeutic agents can include: providing a response surface having data that relates network activation states of a downstream component of a biological network with activation states of at least two upstream components of the network; identifying a desired network activation state of the downstream component from the response surface; identifying the corresponding activation states of the upstream components and identifying at least two therapeutic agents that modulate the upstream components and that are capable of obtaining the desired network activation state. The response surface can be visual or virtual. Optionally, the desired network activation state is an optimal network activation state. | 05-26-2011 |
20110123523 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 05-26-2011 |
20110077208 | EXPRESSION OF SECRETED HUMAN ALPHA-FETOPROTEIN IN TRANSGENIC ANIMALS - The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals. | 03-31-2011 |
20110027291 | METHODS, SYSTEMS AND PRODUCTS FOR PREDICTING RESPONSE OF TUMOR CELLS TO A THERAPEUTIC AGENT AND TREATING A PATIENT ACCORDING TO THE PREDICTED RESPONSE - The invention provides methods for treating patients which methods comprise methods for predicting responses of cells, such as tumor cells, to treatment with therapeutic agents. These methods involve measuring, in a sample of the cells, levels of one or more components of a cellular network and then computing a Network Activation State (NAS) or a Network Inhibition State (NIS) for the cells using a computational model of the cellular network. The response of the cells to treatment is then predicted based on the NAS or NIS value that has been computed. The invention also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm. Biomarkers for predicting responsiveness to treatment with a therapeutic agent that targets a component within the ErbB signaling pathway are also provided. | 02-03-2011 |
20100266584 | ANTIBODIES AGAINST THE ECTODOMAIN OF ERBB3 AND USES THEREOF - The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3. | 10-21-2010 |
20100056761 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 03-04-2010 |
20090291085 | ANTIBODIES AGAINST ERBB3 AND USES THEREOF - The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. For example, the antibodies described herein are capable of binding to ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. | 11-26-2009 |
20090246206 | BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY - Methods for improving the specific binding ability of bispecific binding compositions are described. The bispecific binding compositions are able to target cells by a high affinity targeting domain to a target cell surface marker and a low affinity binding domain that binds specifically to a second cell surface marker, wherein the binding of each domain to its respective cell surface marker increases or decreases, as desired, the biological activity of the respective cell surface markers. The invention further provides bispecific binding agents for use in the methods, as well as uses for the agents. | 10-01-2009 |
20090053254 | RECOMBINANT HUMAN ALPHA-FETOPROTEIN AS AN IMMUNOSUPPRESSIVE AGENT - Disclosed are methods of inhibiting autoreactive immune cell proliferation in a mammal, involving administering to the mammal a therapeutically effective amount of recombinant human alpha-fetoprotein or an immune cell anti-proliferative fragment or analog thereof. | 02-26-2009 |